Shares of Dermira, Inc. (NASDAQ:DERM) have been assigned an average recommendation of “Hold” from the nine research firms that are covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $42.00.
Several research firms recently weighed in on DERM. Mizuho began coverage on Dermira in a report on Thursday, March 30th. They set a “buy” rating and a $42.00 price objective on the stock. BidaskClub raised Dermira from a “sell” rating to a “hold” rating in a report on Thursday, June 15th. Raymond James Financial, Inc. began coverage on Dermira in a report on Thursday, March 16th. They set an “underperform” rating on the stock. Citigroup Inc. began coverage on Dermira in a report on Wednesday, March 15th. They set an “underperform” rating on the stock. They noted that the move was a valuation call. Finally, Guggenheim reissued a “positive” rating and set a $40.00 price objective on shares of Dermira in a report on Thursday, March 2nd.
TRADEMARK VIOLATION NOTICE: “Dermira, Inc. (DERM) Given Consensus Rating of “Hold” by Brokerages” was published by Ticker Report and is the property of of Ticker Report. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.tickerreport.com/banking-finance/2655299/dermira-inc-derm-given-consensus-rating-of-hold-by-brokerages.html.
Shares of Dermira (NASDAQ:DERM) traded up 0.74% during trading on Tuesday, hitting $29.91. The stock had a trading volume of 71,134 shares. Dermira has a one year low of $25.63 and a one year high of $38.75. The stock’s market capitalization is $1.24 billion. The stock has a 50 day moving average price of $28.71 and a 200-day moving average price of $31.30.
In other Dermira news, CEO Thomas G. Wiggans sold 5,000 shares of Dermira stock in a transaction dated Friday, June 2nd. The stock was sold at an average price of $27.52, for a total transaction of $137,600.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Christopher M. Griffith sold 1,312 shares of Dermira stock in a transaction dated Monday, May 15th. The stock was sold at an average price of $27.07, for a total value of $35,515.84. The disclosure for this sale can be found here. Insiders have sold a total of 18,615 shares of company stock worth $586,139 over the last ninety days. Company insiders own 17.30% of the company’s stock.
A number of hedge funds and other institutional investors have recently made changes to their positions in DERM. KCG Holdings Inc. bought a new position in shares of Dermira during the first quarter valued at approximately $215,000. Legal & General Group Plc increased its position in shares of Dermira by 16.3% in the first quarter. Legal & General Group Plc now owns 6,861 shares of the biopharmaceutical company’s stock valued at $236,000 after buying an additional 963 shares during the last quarter. Tocqueville Asset Management L.P. bought a new position in shares of Dermira during the first quarter valued at approximately $256,000. RidgeWorth Capital Management LLC bought a new position in shares of Dermira during the first quarter valued at approximately $297,000. Finally, Airain ltd bought a new position in shares of Dermira during the first quarter valued at approximately $317,000. 84.58% of the stock is currently owned by hedge funds and other institutional investors.
Dermira Company Profile
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.